Global cardiovascular risk assessment in the management of primary hypertension: The role of the kidney

International Journal of Hypertension

Volumn 2013, Issue , 2013, Pages

  Viazzi, Francesca ^a   Leoncini, Giovanna ^a   Pontremoli, Roberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; GLOMERULUS FILTRATION RATE; HEALTH CARE MANAGEMENT; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY; KIDNEY DISEASE; MICROALBUMINURIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; VASCULAR DISEASE;

EID: 84883175404     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2013/542646     Document Type: Review

References (29)

1. Ezzati M., Lopez A. D., Rodgers A., Vander Hoorn S., Murray C. J. L., Selected major risk factors and global and regional burden of disease. Lancet 2002 360 9343 1347 1360 2-s2.0-0037010474 10.1016/S0140-6736(02)11403-6
2. Mancia G., Fagard R., Narkiewicz K., 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013 31 1281 1357
3. Ogden L. G., He J., Lydick E., Whelton P. K., Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension 2000 35 2 539 543 2-s2.0-0033982396
4. Leoncini G., Sacchi G., Viazzi F., Ravera M., Parodi D., Ratto E., Vettoretti S., Tomolillo C., Deferrari G., Pontremoli R., Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. Journal of Hypertension 2002 20 7 1315 1321 2-s2.0-0036628758 10.1097/00004872-200207000-00018
5. Devereux R. B., Alderman M. H., Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 1993 88 4 I 1444 1455 2-s2.0-0027489349
6. Ghali J. K., Liao Y., Cooper R. S., Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. Journal of the American College of Cardiology 1998 31 7 1635 1640 2-s2.0-0031777907 10.1016/S0735-1097(98)00131-4
7. O'Leary D. H., Polak J. F., Kronmal R. A., Manolio T. A., Burke G. L., Wolfson S. K. Jr., Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. New England Journal of Medicine 1999 340 1 14 22 2-s2.0-0033531215 10.1056/NEJM199901073400103
8. Viazzi F., Leoncini G., Parodi D., Ratto E., Vettoretti S., Vaccaro V., Parodi A., Falqui V., Tomolillo C., Deferrari G., Pontremoli R., Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. Journal of the American Society of Nephrology 2005 16 3, supplement S89 S91 2-s2.0-20844443445 10.1681/ASN.2004110956
9. Matsushita K., van der Velde M., Astor B. C., Association of eGFR and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010 375 2073 2081
10. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., Reboldi G., Porcellati C., Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998 97 1 48 54 2-s2.0-0031963796
11. Schmieder R. E., Schlaich M. P., Klingbeil A. U., Martus P., Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrology Dialysis Transplantation 1998 13 3 564 569 2-s2.0-0031908811 10.1093/ndt/13.3.564
12. Dahlöf B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., De Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359 9311 995 1003 2-s2.0-0037160968 10.1016/S0140-6736(02)08089-3
13. Borhani N. O., Mercuri M., Borhani P. A., Buckalew V. M., Canossa-Terris M., Carr A. A., Kappagoda T., Rocco M. V., Schnaper H. W., Sowers J. R., Bond M. G., Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. Journal of the American Medical Association 1996 276 10 785 791 2-s2.0-9544225173 10.1001/jama.276.10.785
14. Zanchetti A., Agabiti Rosei E., Dal Palù C., Leonetti G., Magnani B., Pessina A., The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. Journal of Hypertension 1998 16 11 1667 1676 2-s2.0-0031768673
15. Simon A., Gariépy J., Moyse D., Levenson J., Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001 103 24 2949 2954 2-s2.0-0035912913
16. Zanchetti A., Bond M. G., Hennig M., Neiss A., Mancia G., Dal Palù C., Hansson L., Magnani B., Rahn K.-H., Reid J. L., Rodicio J., Safar M., Eckes L., Rizzini P., Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002 106 19 2422 2427 2-s2.0-0037027501 10.1161/01.CIR.0000039288.86470.DD
17. Turnbull F., Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003 362 9395 1527 1535 2-s2.0-0242654867 10.1016/S0140-6736(03)14739-3
18. Pontremoli R., Microalbuminuria in essential hypertension-its relation to cardiovascular risk factors. Nephrology Dialysis Transplantation 1996 11 11 2113 2115 2-s2.0-0029853687
19. Pontremoli R., Ravera M., Bezante G. P., Viazzi F., Nicolella C., Berruti V., Leoncini G., Del Sette M., Brunelli C., Tomolillo C., Deferrari G., Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. Journal of Hypertension 1999 17 7 993 1000 2-s2.0-0032992049 10.1097/00004872-199917070-00016
20. Jensen J. S., Feldt-Rasmussen B., Strandgaard S., Schroll M., Borch-Johnsen K., Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000 35 4 898 903 2-s2.0-0034082720
21. Olsen M. H., Wachtell K., Borch-Johnsen K., Okin P. M., Kjeldsen S. E., Dahlöf B., Devereux R. B., Ibsen H., A blood pressure independent association between glomerular albumin leakage and electrocardiographic left ventricular hypertrophy. The LIFE study. Journal of Human Hypertension 2002 16 8 591 595 2-s2.0-0036671773 10.1038/sj.jhh.1001450
22. Wachtell K., Ibsen H., Olsen M. H., Borch-Johnsen K., Lindholm L. H., Mogensen C. E., Dahlöf B., Devereux R. B., Beevers G., De Faire U., Fyhrquist F., Julius S., Kjeldsen S. E., Kristianson K., Lederballe-Pedersen O., Nieminen M. S., Okin P. M., Omvik P., Oparil S., Wedel H., Snapinn S. M., Aurup P., Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine 2003 139 11 901 906 2-s2.0-1642535534
23. Ibsen H., Olsen M. H., Wachtell K., Borch-Johnsen K., Lindholm L. H., Mogensen C. E., Dahlöf B., Devereux R. B., De Faire U., Fyhrquist F., Julius S., Kjeldsen S. E., Lederballe-Pedersen O., Nieminen M. S., Omvik P., Oparil S., Wan Y., Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 45 2 198 202 2-s2.0-19944432108 10.1161/01.HYP.0000154082.72286.2a
24. Schmieder R. E., Mann J. F. E., Schumacher H., Gao P., Mancia G., Weber M. A., McQueen M., Koon T., Yusuf S., Changes in albuminuria predict mortality and morbidity in patients with vascular disease. Journal of the American Society of Nephrology 2011 22 7 1353 1364 2-s2.0-79960132102 10.1681/ASN.2010091001
25. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C.-Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New England Journal of Medicine 2004 351 13 1296 1370 2-s2.0-4644221457 10.1056/NEJMoa041031
26. Viazzi F., Leoncini G., Conti N., Tomolillo C., Giachero G., Vercelli M., Deferrari G., Pontremoli R., Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. Journal of Hypertension 2010 28 4 848 855 2-s2.0-78650773021 10.1097/HJH.0b013e328336ed09
27. Leoncini G., Ratto E., Viazzi F., Conti N., Falqui V., Parodi A., Tomolillo C., Deferrari G., Pontremoli R., Global risk stratification in primary hypertension: the role of the kidney. Journal of Hypertension 2008 26 3 427 432 2-s2.0-39849104151 10.1097/HJH.0b013e3282f35c79
28. Levey A. S., Coresh J., Balk E., Kausz A. T., Levin A., Steffes M. W., Hogg R. J., Perrone R. D., Lau J., Eknoyan G., Willis K., National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: evaluation, Classification, and Stratification. Annals of Internal Medicine 2003 139 2 137 I36 2-s2.0-1642502319
29. Haller H., Menne J., Mancia G., Awareness and behaviour of European physicians in relation to microalbuminuria and organ damage: an ESH-endorsed survey. Journal of Hypertension 2010 28 11 2204 2209 2-s2.0-77958515304 10.1097/HJH.0b013e32833cfd40